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One of the current 'hot topics' in clinical trials methodology
is the appropriate use of surrogate endpoints. Surrogate end-
points, sometimes referred to as intermediate endpoints, are
events occurring in the course of a disease that are believed
to be precursors of the ultimate outcome of primary interest.
A well known and well accepted example is high blood
pressure (surrogate) and cardiovascular disease (primary out-
come). Reduction of an elevated blood pressure, in and of
itself, produces no immediate benefit to an individual. It
doesn't improve physical functioning or other aspects of
quality of life. It has been amply demonstrated, however,
that lowering blood pressure reduces the risks of heart attack
and stroke (Collins et al., 1990; SHEP Cooperative Research
Group, 1991; Dahlof et al., 1991). For this reason, clinical
trials of new antihypertensive medications need only demon-
strate that they are effective in lowering blood pressure and
do not have to show a reduced incidence of major vascular
events. While early endpoints are widely used in many
diseases to screen for activity - in cancer - the obvious such
endpoint is tumour response - their use in Phase III studies
to make definitive determinations about therapeutic efficacy
is more controversial.
The example of blood pressure effectively illustrates the
primary rationale for using surrogate endpoints. They pro-
vide potential for accelerating evaluation of new therapies,
since use of earlier endpoints implies more rapid completion
of trials. But there are other reasons why surrogate endpoints
might be desirable. They might be observable more easily or
less invasively or less expensively than the 'true' outcome.
Studies of nutritional interventions to avert loss of body
mass, for example, have often relied on such surrogate
measures as weight and anthropometric measures such as
skinfold thickness, since the 'gold standard' measures of
body mass are exceedingly complex and the availability of
the necessary equipment for such testing is quite limited. Yet
another reason for the use of surrogate endpoints, one that is
particularly relevant to cancer studies, is the 'competing risks'
problem when a long-term endpoint such as survival is used.
If a substantial proportion of the study population might be
expected to die of causes unrelated to the disease under
study, an earlier endpoint might actually provide a more
precise estimate of the treatment effect. Even when most
patients will eventually succumb to the disease in question,
survival comparisons could become clouded by effects of
concomitant or salvage therapies administered later in the
course of treatment.
Because cancer is a life-threatening disease, the endpoint of
primary interest in studies to evaluate and/or compare
therapeutic strategies must be mortality. For many types of
cancer, and for most cancers diagnosed at advanced stages of
disease, it is unfortunately the case that survival is a perfectly
feasible study endpoint because of the short life expectancy
following diagnosis of these neoplasms and the minimal
efficacies of available treatments. In other situations, how-
ever, survival studies will take many years to complete, and
will require very large sample sizes to offset the expected
dilution of observed differences due to, for example, use of
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salvage therapies or competing risks of death from other
causes. This is frequently the case in studies of adjuvant
therapies, particularly when the initial 'curative' therapy,
usually surgery or radiotherapy, is substantially efficacious.
Assessing survival may also be problematic in diseases such
as head and neck cancer, in which patients are at risk of
death from non-cancer causes.
There are two major problems with the use of surrogate
endpoints to make definitive decisions about drugs. The first
is that a drug may have the desired effect on the surrogate,
but may have a limited effect on the clinical outcome of
interest, or may have other adverse effects that outweigh the
benefit, so that the ultimate clinical impact is null or even
negative. An example going back some years is diethylstibest-
rol (DES) for treatment of prostate cancer. A review of
several trials performed by the Veterans Administration
between 1960 and 1975 showed that high doses of DES
clearly induced greater tumour shrinkage and delayed pro-
gression of disease compared to a low dose of DES and a
placebo. Nevertheless, overall survival was definitely better
on the latter arms, due almost surely to the cardiotoxicity of
this agent (Byar, 1973). Another even more dramatic example
in a non-cancer context was the finding in a double-blind
randomised trial by The Cardiac Arrhythmia Suppression
Trial (CAST) Investigators (1989) that drugs that were
effective in preventing arrhythmias in patients recovering
from a myocardial infarction were associated with higher
mortality, despite the fact that arrhythmias are known to be
associated with poorer survival.
The converse may occur; all or part of a drug's benefit
may not be mediated through the proposed surrogate so that
the treatment effect may be underestimated if the true out-
come is not assessed. In a recent study, interferon y for
chronic granulomatous disease was found to be highly
efficacious in protecting against the occurrence of serious
bacterial infections, but the laboratory markers that had been
thought to mediate the utility of this therapy were unaffected
(The International Chronic Granulomatous Disease
Cooperative Study Group, 1991).
The second problem is that a surrogate that appears ap-
propriate to evaluate one class of treatments may not be
appropriate to evaluate other treatments with different
mechanisms of action. If treatments are interrupting disease
via different mechanisms, there is no guarantee that a more
proximal endpoint will equally well reflect the effects of these
treatments. This problem may not be a serious one for
tumour response, the prototype surrogate endpoint for
cancer studies, since whatever the mechanism of action,
tumour growth must be thwarted in order to improve
ultimate outcome. It may, however, be of more concern for
laboratory markers or other less direct measures of neoplas-
tic activity, and may be particularly worrisome when we are
comparing biologic or hormonal agents with more traditional
cytotoxic therapy. A related issue is knowing exactly how to
use such a marker to assess benefit. Is it the size of the
change (absolute or relative to baseline level) that is impor-
tant, or whether normal levels are achieved (and/or for how
long), or the proportion of patients achieving a desired level?
The size of the treatment benefit, and therefore the inter-
pretation of the results of comparative trials, may be very
dependent on the way the endpoint is defined.
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As the examples demonstrate, these problems are by no
means purely theoretical. Fatal adverse effects are sometimes
observed in studies evaluating adjuvant therapies for sur-
gically resected tumours, precisely the type of long-term
study in which intermediate endpoints would be attractive. In
these studies, tumour recurrence is often the primary end-
point. This is a sensible approach, since the intent of
adjuvant therapy is to improve the probability that the
patient has in fact been cured of neoplastic disease. Never-
theless, the importance of obtaining the ultimate survival
results cannot be overstated. The serious side effects, includ-
ing drug-induced leukaemias, that have been reported for
some of these agents (Reimer et al., 1977; Bergsagel et al.,
1979; Coltman & Dixon, 1982; Boice et al., 1983) point to
the need to verify overall benefit with respect to survival.
An important practical issue concerning the use of sur-
rogate endpoints is that of measurement variability. Other
than death, all outcomes are assessed with some degree of
uncertainty, due to some combination of measurement error
and inherent within-subject biologic variability. The level of
uncertainty of any given measure must be taken into account
when considering its potential reliability as a trial endpoint.
The imprecision of manual and radiologic measurements of
tumour size has been well documented (Moertel & Hanley,
1976; Lavin & Flowerdew, 1980; Warr et al., 1984);
laboratory measures are likely to be at least as variable.
While variability can always be reduced by replicate
measurements at the defined time points, this approach is
often impractical because of financial constraints as well as
patient unwillingness to provide multiple samples. The
variability of an outcome measure should be an important
factor in any decision to use this measure as a basis for
definitive evaluation of new therapies, especially when studies
are non blinded and when the determination of the measure
is at all subjective.
Recently, the use of laboratory markers as trial endpoints
has received a great deal of discussion. Some widely used
markers such as carcinoembryonic antigen (CEA) in colorec-
tal cancer and CA 125 in ovarian cancer have been shown to
be inadequately predictive for this purpose (Fayers et al.
(1993), Ellenberg & Hamilton (1989), NIH Consensus Con-
ference (1981)). There has been increasing interest in
prostate-specific antigen (PSA) which has been shown to be
highly correlated with tumour volume in men with prostatic
cancer (Stamey et al., 1987). Since much prostate cancer is
non measurable, the availability of a reliable laboratory
marker would greatly expand the patient population for
Phase II studies to determine tumour activity. For definitive
evaluation of clinical benefit, however, it is less clear that this
marker or other markers will obviate the need to perform
survival studies. While there are ample data to demonstrate
the prognostic value ofPSA, as exist for CEA and CA 125 as
well, data demonstrating that advanced-stage patients who
experience the largest treatment-induced reductions in PSA
level, or those early patients who experience treatment-
prolonged intervals of PSA negativity, will in fact have a
lower risk of death, are only now beginning to emerge
(Gerber et al., 1990; Seidman et al., 1992; Scher et al., 1992).
Until such data are fully available and are shown to be
consistent across treatments, determining relative efficacy of
therapeutic approaches on the basis of PSA will remain
problematic.
These issues have been widely discussed in the AIDS con-
text (Weiss & Mazade, 1990; Machado et al., 1990; Jacobson
et al., 1991; Ellenberg, 1991; Lagakos & Hoth, 1992). The
CD4+ lymphocyte count is a well documented predictor of
outcome in HIV-infected patients, but changes in this marker
do not appear to be as highly correlated with clinical pro-
gression and survival as one would like in order to use this
marker as a basis for evaluating and comparing therapeutic
efficacy (De Gruttola et al., in press; Tsiatis et al., 1992; Choi
et al., 1993). This may be partially due to the fact that
measurements of CD4+ cells are known to be highly
variable (Weiss & Mazade, 1990; Taylor et al., 1989; Gelman
et al., in press). However, the recently reported result that in
a large placebo-controlled trial of zidovudine in asymp-
tomatic HIV-infected individuals, the CD4+ count was
affected, but clinical progression and mortality were not
(Aboulker & Swart, 1993), raises more doubts that this
marker can serve as a reliable surrogate for clinical out-
comes.
Nevertheless, as in prostate cancer, changes in the marker
are well established as indicators of advancing disease, and
are frequently used by physicians to determine when
modification of the therapeutic approach may be required. In
this situation it becomes more difficult to conduct trials using
clinically meaningful endpoints, since changes in therapy
mandated by these earlier marker events may blur any com-
parison based on later clinical endpoints.
In both AIDS and cancer, there exists a real sense of
urgency to evaluate promising therapies and to make widely
available those that prove efficacious. There are certainly
risks inherent in waiting longer for answers from survival-
based trials; current patients may be deprived of improved
treatments. Such concerns must be weighed against the risk
of adopting therapies on the basis of early data without the
assurance that current as well as future patients will
ultimately benefit from them.
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